We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Regeneron (REGN) Gets FDA Nod for Libtayo's Label Expansion
Read MoreHide Full Article
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) announced that the FDA has approved the PD-1 inhibitor Libtayo (cemiplimab-rwlc) for another indication.
The drug has been approved in combination with platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations. The drug has been approved for patients who either have metastatic or locally advanced tumors that are not candidates for surgical resection or definitive chemoradiation. Patients may be treated with this combination irrespective of PD-L1 expression or histology.
The approval was based on data from the global phase III trial, EMPOWER-Lung 3, which evaluated Libtayo in combination with a physician's choice of platinum-doublet chemotherapy (Libtayo combination), compared to platinum-doublet chemotherapy alone.
The drug is already approved for advanced cutaneous squamous cell carcinoma and adults with NSCLC. It is also approved for advanced cutaneous squamous cell carcinoma and basal cell carcinoma.
The latest approval is the second advanced NSCLC indication that expands the patient population eligible for a Libtayo-based regimen to include the combination treatment with chemotherapy, irrespective of PD-L1 expression levels. Libtayo is now approved for extending the survival of patients with advanced non-small cell lung cancer as both a monotherapy in high PD-L1 expressors and in combination with chemotherapy, irrespective of PD-L1 expression levels.
Libtayo sales came in at $143.2 million in the third quarter of 2022, up 20% year over year.
Regeneron’s shares have gained 19.1% in the year so far against the industry’s decline of 20.6%.
Image Source: Zacks Investment Research
Please note that prior to Jul 1, 2022, Regeneron recorded net product sales of Libtayo in the United States and Sanofi (SNY - Free Report) recorded net product sales of Libtayo outside the United States.
Effective Jul 1, 2022, Regeneron records global net product sales of Libtayo outside the United States and pays a royalty to Sanofi on such sales.
Regeneron’s third-quarter results were strong, reflecting broad-based growth. Solid demand for Eylea and Dupixent maintained momentum for the company.
Growth in Eylea and Dupixent through further penetration in existing indications and a promising late-stage pipeline set the momentum for growth. The company’s progress with Libtayo will enable it to further diversify its revenue base.
Regeneron currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the healthcare sector are Puma Biotechnology (PBYI - Free Report) and Dynavax (DVAX - Free Report) . While Puma sports a Zacks Rank #1 (Strong Buy), Dynavax carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, loss estimates for Puma have narrowed to 6 cents from 16 cents. Puma also surpassed estimates in three of the trailing four quarters, with the average being 201.37%.
Earnings estimates for Dynavax have increased to $1.74 from $1.15 for 2022 over the past 90 days. Earnings of Dynavax surpassed estimates in two of the trailing four quarters.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Regeneron (REGN) Gets FDA Nod for Libtayo's Label Expansion
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) announced that the FDA has approved the PD-1 inhibitor Libtayo (cemiplimab-rwlc) for another indication.
The drug has been approved in combination with platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations. The drug has been approved for patients who either have metastatic or locally advanced tumors that are not candidates for surgical resection or definitive chemoradiation. Patients may be treated with this combination irrespective of PD-L1 expression or histology.
The approval was based on data from the global phase III trial, EMPOWER-Lung 3, which evaluated Libtayo in combination with a physician's choice of platinum-doublet chemotherapy (Libtayo combination), compared to platinum-doublet chemotherapy alone.
The drug is already approved for advanced cutaneous squamous cell carcinoma and adults with NSCLC. It is also approved for advanced cutaneous squamous cell carcinoma and basal cell carcinoma.
The latest approval is the second advanced NSCLC indication that expands the patient population eligible for a Libtayo-based regimen to include the combination treatment with chemotherapy, irrespective of PD-L1 expression levels. Libtayo is now approved for extending the survival of patients with advanced non-small cell lung cancer as both a monotherapy in high PD-L1 expressors and in combination with chemotherapy, irrespective of PD-L1 expression levels.
Libtayo sales came in at $143.2 million in the third quarter of 2022, up 20% year over year.
Regeneron’s shares have gained 19.1% in the year so far against the industry’s decline of 20.6%.
Image Source: Zacks Investment Research
Please note that prior to Jul 1, 2022, Regeneron recorded net product sales of Libtayo in the United States and Sanofi (SNY - Free Report) recorded net product sales of Libtayo outside the United States.
Effective Jul 1, 2022, Regeneron records global net product sales of Libtayo outside the United States and pays a royalty to Sanofi on such sales.
Regeneron’s third-quarter results were strong, reflecting broad-based growth. Solid demand for Eylea and Dupixent maintained momentum for the company.
Growth in Eylea and Dupixent through further penetration in existing indications and a promising late-stage pipeline set the momentum for growth. The company’s progress with Libtayo will enable it to further diversify its revenue base.
Regeneron currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the healthcare sector are Puma Biotechnology (PBYI - Free Report) and Dynavax (DVAX - Free Report) . While Puma sports a Zacks Rank #1 (Strong Buy), Dynavax carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, loss estimates for Puma have narrowed to 6 cents from 16 cents. Puma also surpassed estimates in three of the trailing four quarters, with the average being 201.37%.
Earnings estimates for Dynavax have increased to $1.74 from $1.15 for 2022 over the past 90 days. Earnings of Dynavax surpassed estimates in two of the trailing four quarters.